Document is current
Any future updates will be listed below
-
Authors
Kim, Yongsung https://orcid.org/0000-0002-2196-3063
Cheng, Weiqiu https://orcid.org/0000-0003-4001-8662
Cho, Chun-Seok https://orcid.org/0000-0002-9589-5745
Hwang, Yongha https://orcid.org/0000-0002-4345-581X
Si, Yichen https://orcid.org/0000-0001-5576-3054
Park, Anna https://orcid.org/0000-0002-7323-9114
Schrank, Mitchell
Hsu, Jer-En https://orcid.org/0000-0002-2968-1853
Anacleto, Angelo
Xi, Jingyue
Kim, Myungjin
Pedersen, Ellen
Koues, Olivia I.
Wilson, Thomas
Lee, ChangHee
Jun, Goo
Kang, Hyun Min
Lee, Jun Hee https://orcid.org/0000-0002-2200-6011
-
Funding
Funding for this research was provided by:
A. Alfred Taubman Medical Research Institute (Taubman Institute Innovation Project, Taubman Institute Innovation Project)
U.S. Department of Health & Human Services | National Institutes of Health (T32AG000114, T32AG000114, K01AG061236 R01AG079163, R01HG011031 HHSN268201800002I)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
- License Information
-
More Information
Article History
Received: 19 March 2024
Accepted: 21 August 2024
First Online: 31 October 2024
Competing interests
: H.M.K. owns stock in Regeneron Pharmaceuticals. J.H.L. is an inventor on a patent and pending patent applications related to Seq-Scope.
